Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study

BACKGROUND: Anti‐TNF antibodies were the first biologic treatment option for patients with inflammatory bowel diseases. AIMS: To assess length of treatment persistence of first anti‐TNF therapy and influencing factors used in the standard care of patients with inflammatory bowel diseases. METHODS: S...

Descripción completa

Detalles Bibliográficos
Autores principales: Blesl, Andreas, Binder, Lukas, Högenauer, Christoph, Wenzl, Heimo, Borenich, Andrea, Pregartner, Gudrun, Berghold, Andrea, Mestel, Sigrid, Kump, Patrizia, Baumann‐Durchschein, Franziska, Petritsch, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Treatment Persistence with Anti‐tnf Agents in IBD
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453765/
https://www.ncbi.nlm.nih.gov/pubmed/34151449
http://dx.doi.org/10.1111/apt.16478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453765/
https://www.ncbi.nlm.nih.gov/pubmed/34151449
http://dx.doi.org/10.1111/apt.16478

Ejemplares similares